Lymphadenopathy-associated-virus infection and acquired immunodeficiency syndrome.

Elevated levels of mRNA can account for the trans-activation of human immunodeficiency virus. Proc Natl Acad Sci U S A (1986) 6.57

Persistent infection of rabbits with bovine leukemia virus associated with development of immune dysfunction. J Virol (1989) 0.97

Individuals infected with HIV possess antibodies against IL-2. Immunology (1988) 0.85

Polyclonal T cell elimination by prolonged immunostimulation in an experimental model. Clin Exp Immunol (1997) 0.75

Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 43.61

T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature (1985) 21.57

Genome organization and transactivation of the human immunodeficiency virus type 2. Nature (1987) 11.79

Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science (1984) 10.38

Genetic variability of the AIDS virus: nucleotide sequence analysis of two isolates from African patients. Cell (1986) 9.01

Nucleotide sequence of the visna lentivirus: relationship to the AIDS virus. Cell (1985) 7.86

HIV-1 genome nuclear import is mediated by a central DNA flap. Cell (2000) 5.87

Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology (1991) 5.54

HIV F/3' orf encodes a phosphorylated GTP-binding protein resembling an oncogene product. Nature (1987) 5.45

Single amino-acid changes in HIV envelope affect viral tropism and receptor binding. Nature (1989) 5.12

Human immunodeficiency viruses. Science (1986) 4.34

Adaptation of lymphadenopathy associated virus (LAV) to replication in EBV-transformed B lymphoblastoid cell lines. Science (1984) 4.02

Inactivation of lymphadenopathy-associated virus by heat, gamma rays, and ultraviolet light. Lancet (1985) 3.27

Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins. J Virol (1989) 3.05

Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol (1996) 3.05

Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut (2008) 2.97

A possible subunit structure of Rous sarcoma virus RNA. J Gen Virol (1969) 2.96

Simian immunodeficiency virus replicates to high levels in sooty mangabeys without inducing disease. J Virol (1998) 2.94

Molecular cloning and polymorphism of the human immune deficiency virus type 2. Nature (1987) 2.86

Apoptosis in AIDS. Science (1993) 2.86

The specificity of the human immunodeficiency virus type 2 transactivator is different from that of human immunodeficiency virus type 1. EMBO J (1987) 2.85

HIV/HTLV gene nomenclature. Nature (1988) 2.72

Detection of IgG antibodies to lymphadenopathy-associated virus in patients with AIDS or lymphadenopathy syndrome. Lancet (1984) 2.56

VPX mutants of HIV-2 are infectious in established cell lines but display a severe defect in peripheral blood lymphocytes. EMBO J (1989) 2.45

The cytopathic effect of HIV is associated with apoptosis. Virology (1991) 2.43

The human and simian immunodeficiency viruses HIV-1, HIV-2 and SIV interact with similar epitopes on their cellular receptor, the CD4 molecule. AIDS (1988) 2.35

HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet (1998) 2.32

Dendritic cells are required for the development of chronic eosinophilic airway inflammation in response to inhaled antigen in sensitized mice. J Immunol (1998) 2.32

Human immunodeficiency virus type 2 infection associated with AIDS in West Africa. N Engl J Med (1987) 2.32

Programmed cell death in AIDS-related HIV and SIV infections. AIDS Res Hum Retroviruses (1993) 2.29

Identification and antigenicity of the major envelope glycoprotein of lymphadenopathy-associated virus. Virology (1985) 2.23

Molecular cloning of lymphadenopathy-associated virus. Nature (1985) 2.22

Inactivation of lymphadenopathy associated virus by chemical disinfectants. Lancet (1984) 2.19

Human immunodeficiency virus type 1-infected monocytic cells can destroy human neural cells after cell-to-cell adhesion. Ann Neurol (1992) 2.04

Heterogeneity of mouse spleen dendritic cells: in vivo phagocytic activity, expression of macrophage markers, and subpopulation turnover. J Immunol (1998) 2.01

Effects of mutations in hyperconserved regions of the extracellular glycoprotein of human immunodeficiency virus type 1 on receptor binding. J Virol (1989) 1.97

Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat Med (1999) 1.97

Prevalence of antibodies to lymphadenopathy-associated retrovirus in African patients with AIDS. Science (1984) 1.95

[Presence of a double chain ribonucleic acid in animal cells]. C R Acad Sci Hebd Seances Acad Sci D (1968) 1.94

Characterization of the RNA dependent DNA polymerase of a new human T-lymphotropic retrovirus (lymphadenopathy associated virus). Biochem Biophys Res Commun (1984) 1.94

Characterization of human immunodeficiency virus type 2 envelope glycoproteins: dimerization of the glycoprotein precursor during processing. J Virol (1989) 1.93

Virus excretion in the cervicovaginal secretions of pregnant and nonpregnant HIV-infected women. J Acquir Immune Defic Syndr (1993) 1.91

A microtransfection method using the luciferase-encoding reporter gene for the assay of human immunodeficiency virus LTR promoter activity. Gene (1990) 1.90

Dendritic cells as the terminal stage of monocyte differentiation. J Immunol (1998) 1.87

Improved antigenicity of the HIV env protein by cleavage site removal. Protein Eng (1988) 1.87

Inactivation, by UV-, x-, and gamma-radiations, of the infecting and transforming capacities of polyoma virus. Virology (1967) 1.86

A rapid and simple colorimetric test for the study of anti-HIV agents. AIDS Res Hum Retroviruses (1988) 1.80

The multitude and diversity of environmental carcinogens. Environ Res (2007) 1.73

Antibodies to the core protein of lymphadenopathy-associated virus (LAV) in patients with AIDS. Science (1984) 1.73

Differentiation of human dendritic cells from monocytes in vitro. Eur J Immunol (1997) 1.72

AIDS in 1988. Sci Am (1988) 1.71

Antimoniotungstate (HPA 23) treatment of three patients with AIDS and one with prodrome. Lancet (1985) 1.70

Increased nuclease activity in cells treated with pppA2'p5'A2'p5' A. Proc Natl Acad Sci U S A (1979) 1.66

Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. Proc Natl Acad Sci U S A (1999) 1.66

Concomitant infection by human herpesvirus 6, HTLV-I, and HIV-2. Lancet (1988) 1.66

Autoantibodies typical of non-organ-specific autoimmune diseases in HIV-seropositive patients. AIDS (1992) 1.65

Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci U S A (1993) 1.63

Absence of antibodies to AIDS virus in haemophiliacs treated with heat-treated Factor VIII concentrate. Lancet (1985) 1.60

Division rate and phenotypic differences discriminate alloreactive and nonalloreactive T cells transferred in lethally irradiated mice. Blood (2001) 1.60

Acute neuropathy coincident with seroconversion for anti-LAV/HTLV-III. Lancet (1986) 1.58

A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. AIDS Res Hum Retroviruses (1995) 1.56

The influence of interleukin (IL)-4, IL-13, and Flt3 ligand on human dendritic cell differentiation from cord blood CD34+ progenitor cells. Exp Hematol (1998) 1.51

Lymphadenopathy-associated viral antibody in AIDS. Immune correlations and definition of a carrier state. N Engl J Med (1984) 1.51

Deficient LAV1 neutralising capacity of sera from patients with AIDS or related syndromes. Lancet (1985) 1.48

The mechanisms of inhibition of human IL 2 production. II. PGE2 induction of suppressor T lymphocytes. J Immunol (1984) 1.46

Isolation and envelope sequence of a highly divergent HIV-1 isolate: definition of a new HIV-1 group. Virology (1994) 1.46

Prolonged allograft survival through conditional and specific ablation of alloreactive T cells expressing a suicide gene. Transplantation (2000) 1.43

Early viral replication in the brain of SIV-infected rhesus monkeys. Am J Pathol (1991) 1.42

Structure and variations of feline immunodeficiency virus envelope glycoproteins. Virology (1993) 1.41

Detection of primary cytotoxic T lymphocytes specific for the envelope glycoprotein of HIV-1 by deletion of the env amino-terminal signal sequence. Eur J Immunol (1990) 1.40

The susceptibility to X4 and R5 human immunodeficiency virus-1 strains of dendritic cells derived in vitro from CD34(+) hematopoietic progenitor cells is primarily determined by their maturation stage. Blood (1999) 1.37

Role of N-linked glycans of envelope glycoproteins in infectivity of human immunodeficiency virus type 1. J Virol (1990) 1.35

Dendritic cells route human immunodeficiency virus to lymph nodes after vaginal or intravenous administration to mice. J Virol (1998) 1.35

AIDS-associated mycoplasmas. Annu Rev Microbiol (1994) 1.34

Three populations of mouse lymph node dendritic cells with different origins and dynamics. J Immunol (1998) 1.33

Variable course of primary simian immunodeficiency virus infection in lymph nodes: relation to disease progression. J Virol (1994) 1.33

Interferon messenger RNA: translation in heterologous cells. Proc Natl Acad Sci U S A (1972) 1.32

Loss of CD4 membrane expression and CD4 mRNA during acute human immunodeficiency virus replication. J Exp Med (1988) 1.31

Lifestyle-related factors and environmental agents causing cancer: an overview. Biomed Pharmacother (2007) 1.29

Characterization of the human CD4 gene promoter: transcription from the CD4 gene core promoter is tissue-specific and is activated by Ets proteins. Proc Natl Acad Sci U S A (1993) 1.29

The maturation of dendritic cells results in postintegration inhibition of HIV-1 replication. J Immunol (2001) 1.29

Biosynthesis of mouse interferon by translation of its messenger RNA in a cell-free system. Proc Natl Acad Sci U S A (1975) 1.27

Human microglial cells: characterization in cerebral tissue and in primary culture, and study of their susceptibility to HIV-1 infection. Ann Neurol (1991) 1.26

Molecular evidence for nosocomial transmission of human immunodeficiency virus from a surgeon to one of his patients. J Virol (1998) 1.26

Transmembrane envelope glycoproteins of human immunodeficiency virus type 2 and simian immunodeficiency virus SIV-mac exist as homodimers. J Virol (1990) 1.26

A "distant" bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. Hum Gene Ther (1997) 1.25

A monoclonal antibody against LAV gag precursor: use for viral protein analysis and antigenic expression in infected cells. J Immunol (1986) 1.25

HIV infection of monocytic cells: rôle of antibody-mediated virus binding to Fc-gamma receptors. AIDS (1989) 1.24

Kaposi's sarcoma and new herpesvirus. Lancet (1995) 1.24